PubMed Health⌕ Search

Biomedical subjects

R Valsecchi

Publications and source records attributed to R Valsecchi.

At least 73 records · Page 4Linked to original sources
PubMed1988

HLA-DR and DQ antigens in lichen planus.

A study on HLA-DR and DQ typing in 40 patients with lichen planus (26 males and 14 females) and in 92 normal blood donors of both sexes was performed. Twenty-seven patients had cutaneous lesions, 11 cutaneous and mucosal involvement and 2 patients had oral erosive lesions. Serological typing revealed a highly significant increase of HLA-DR 1 antigen in the patient group. No difference has been observed on the prevalence of DR1 antigen among the different clinical status of the disease.

Adult↗
PubMed1986

Topical immunotherapy of alopecia areata. A follow-up study.

Ninety-six patients suffering from alopecia areata have been treated with topical immunotherapy. Fifty-one have been treated with dinitrochlorobenzene and 45 with squaric acid dibutylester. Analysis of our group showed that 55 patients out of those 96, who entered the study, experienced hair regrowth during a period of 6-17 weeks of treatment. Of these 55 patients, 25 (45.4%) had a recurrence of AA and 30 (53.6%) had a persistent regrowth during a follow-up of 16 months-6 years. The severity and early development of flare-up and induced allergic contact dermatitis have been the principal factors that have influenced the clinical results.

Administration, Topical↗
PubMed1986

Double-blind comparison of astemizole and terfenadine in the treatment of chronic urticaria.

Two new non-sedating antihistamines, astemizole (10 mg per day) and terfenadine (120 mg per day), were compared in a double-blind randomized study in 42 adult patients suffering from chronic urticaria. The trial lasted 4 weeks. Patients were evaluated at 2 and 4 weeks and kept a daily diary of their symptoms. There was a statistically significant decrease in pruritus, erythema and urticaria papules in both groups throughout the study. Changes in papule size, number and frequency were greater in the astemizole group though not significantly different to the terfenadine group. The effect of astemizole increased with time whereas that of terfenadine decreased after about 3 weeks of treatment. Astemizole was globally considered to be the most effective drug by both investigator and patients, with excellent/good results in 77% of the patients compared with 55% to 60% in the terfenadine group. Both drugs were reported to be more effective and faster acting than other antihistamines taken previously. Side-effects were infrequent and minor in both groups.

Adolescent↗
PubMed1985

Elimination kinetics of thiopentone in mothers and their newborn infants.

The elimination kinetics of thiopentone was studied in 7 newborns delivered by Caesarean section and in their mothers who had received the drug for induction of anaesthesia. At delivery, 4-9 min after induction, drug concentrations in cord blood were half those in material blood. The mean half-life of thiopentone in the newborns was about double that in their mothers (15 vs 7 h) confirming a disposition similar to other barbiturates. For the first time renal clearance of thiopentone was estimated in the newborn; 0.074 ml/h/kg. Only 0.0007% (about 2 micrograms) of the maternal dose was recovered in the urine of newborns over 36 h. Pentobarbitone, an active metabolite, was not detected in any specimen. The findings demonstrate the reliability of current anaesthesiological technique (thiopentone-succinylcholine-oxygen) with minimal fetal exposure to the drug.

Cesarean Section↗
PubMed1985

Tego dermatitis.

Explore the source record for details and available documents.

Adult↗
PubMed1985

Peripheral T-cell subsets in patients with alopecia areata in different clinical phases.

An analysis of T-cell subpopulations was carried out in the peripheral blood of 21 subjects with alopecia areata (AA) of the scalp in various phases of its evolution and in 18 healthy control subjects by means of different monoclonal antibodies of OKT series (T3, T4, T8, T11). Patients with AA in active phase showed a significant reduction of OKT 8+ cells (p less than 0.002) and a significant increase of OKT 4+ cells (p less than 0.002) versus controls. On the contrary, patients with regrowing hair showed a significant increase of circulating OKT 8+ cells compared with controls (p less than 0.002). No abnormality in the distribution of T-cell subsets in patients with AA in stable phase has been observed.

Adolescent↗